Last reviewed · How we verify
EBR/GZR (elbasvir/grazoprevir)
Elbasvir/grazoprevir is a fixed-dose combination of an NS5A inhibitor and an NS3/4A protease inhibitor that blocks hepatitis C virus replication.
Elbasvir/grazoprevir is a fixed-dose combination of an NS5A inhibitor and an NS3/4A protease inhibitor that blocks hepatitis C virus replication. Used for Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6.
At a glance
| Generic name | EBR/GZR (elbasvir/grazoprevir) |
|---|---|
| Also known as | Zepatier |
| Sponsor | University of Florida |
| Drug class | Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor |
| Target | Hepatitis C virus NS5A protein and NS3/4A serine protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Elbasvir inhibits the NS5A protein, which is essential for hepatitis C virus RNA replication and virion assembly. Grazoprevir inhibits the NS3/4A serine protease, which is required for processing of the HCV polyprotein. Together, these two direct-acting antivirals (DAAs) target different steps of the HCV lifecycle, providing potent and synergistic viral suppression.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
- Elevated bilirubin
Key clinical trials
- Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) (PHASE2)
- Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients (PHASE3)
- Study of Oral Treatments for Hepatitis C (PHASE4)
- An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061) (PHASE3)
- Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096) (PHASE4)
- EBR/GZR for HCV-1b Patients Receiving Hemodialysis (PHASE4)
- Impact of Hepatitis C Therapy and Bone Health (PHASE4)
- Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EBR/GZR (elbasvir/grazoprevir) CI brief — competitive landscape report
- EBR/GZR (elbasvir/grazoprevir) updates RSS · CI watch RSS
- University of Florida portfolio CI